US 12,436,154 B2
Detection of antibodies against RAN proteins from serum and tissue lysates
Laura Ranum, Gainesville, FL (US); Lauren A. Laboissonniere, Gainesville, FL (US); and Lien Nguyen, Gainesville, FL (US)
Assigned to University of Florida Research Foundation, Incorporated, Gainesville, FL (US)
Appl. No. 17/761,764
Filed by University of Florida Research Foundation, Incorporated, Gainesville, FL (US)
PCT Filed Sep. 18, 2020, PCT No. PCT/US2020/051671
§ 371(c)(1), (2) Date Mar. 18, 2022,
PCT Pub. No. WO2021/055880, PCT Pub. Date Mar. 25, 2021.
Claims priority of provisional application 62/904,612, filed on Sep. 23, 2019.
Claims priority of provisional application 62/903,689, filed on Sep. 20, 2019.
Prior Publication US 2022/0373559 A1, Nov. 24, 2022
Int. Cl. G01N 33/68 (2006.01); G01N 21/66 (2006.01); G01N 33/543 (2006.01)
CPC G01N 33/6854 (2013.01) [G01N 21/66 (2013.01); G01N 33/54366 (2013.01); G01N 2458/30 (2013.01); G01N 2800/52 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A method comprising:
(i) detecting in a first biological sample obtained from a subject one or more anti-RAN protein antibodies using an electrochemiluminescence-based immunoassay;
(ii) detecting in a second biological sample obtained from the subject one or more anti-RAN protein antibodies using an electrochemiluminescence-based immunoassay, wherein the second biological sample is obtained after administration of a therapeutic agent to the subject;
(iii) comparing an amount of anti-RAN protein antibodies detected in the second biological sample to an amount of anti-RAN protein antibodies detected in the first biological sample;
(iv) identifying the subject as having a change in one or more anti-RAN protein antibody levels when the amount of anti-RAN protein antibodies detected in the second biological sample is different than the amount of anti-RAN protein antibodies detected in the first biological sample; and
(v) administering to the subject a vaccine against a RAN protein-associated disease or disorder when the second biological sample contains a decreased level of anti-RAN protein antibodies, relative to the first biological sample.